TLPH biotech catalysts & pipeline

TALPHERA INC · Data as of 2026-10-25

Upcoming catalysts

Niyad — Clinical data readout

2026

Received an investigational device exemption, or IDE, and Breakthrough Device Designation from the United States Food and Drug Administration, or FDA, and registrational trial is ongoing with completion expected in 2026.

Source filing

Niyad — Regulatory decision

late 2026

Cash and investments at September 30, 2025 were $21.3 million; combined with conditional future tranches of previous financings, expect sufficient cash through a potential PMA approval of Niyad in late 2026

Source filing

Explore the free biotech catalyst calendar